These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38148411)
1. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation. Zhang Y; Guo J; Chen W; Zhao L; Huang X Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411 [TBL] [Abstract][Full Text] [Related]
2. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation. Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429 [TBL] [Abstract][Full Text] [Related]
3. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412 [TBL] [Abstract][Full Text] [Related]
4. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma]. Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356 [TBL] [Abstract][Full Text] [Related]
5. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center]. Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616 [No Abstract] [Full Text] [Related]
6. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Tun AM; Wang Y; Maliske S; Micallef I; Inwards DJ; Habermann TM; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB Transplant Cell Ther; 2024 Oct; 30(10):1001.e1-1001.e12. PubMed ID: 38996973 [TBL] [Abstract][Full Text] [Related]
7. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823 [TBL] [Abstract][Full Text] [Related]
8. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974 [TBL] [Abstract][Full Text] [Related]
9. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703 [TBL] [Abstract][Full Text] [Related]
10. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK. Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT. Waszczuk-Gajda A; Gras L; de Wreede LC; Sirait T; Illes A; Ozkurt ZN; Snowden JA; Arat M; Bulabois CE; Niederland J; Sever M; Paneesha S; Potter V; Gadisseur A; Chalopin T; Van Gorkom G; López JM; Kerre T; Drozd-Sokolowska J; Raj K; Hayden PJ; Beksac M; Yakoub-Agha I; McLornan DP; Schönland S Bone Marrow Transplant; 2023 Apr; 58(4):424-429. PubMed ID: 36681775 [TBL] [Abstract][Full Text] [Related]
13. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108 [TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
16. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy. Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963 [TBL] [Abstract][Full Text] [Related]
18. The Role of Autologous Stem Cell Transplantation in Amyloidosis. Vaxman I; Dispenzieri A Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250 [TBL] [Abstract][Full Text] [Related]
20. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]